The role of early warning symptoms in the detection and prevention of relapse in schizophrenia

References

• Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Australian and New Zealand Journal of Psychiatry 2000; 34: S26–S34
   PubMed Web of Science ®Google Scholar
• Wiersma D, Nienhuis F J, Slooff C J, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin 1998; 24: 75–85
   PubMed Web of Science ®Google Scholar
• Loebel A, Lieberman J, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in firstepisode schizophrenia. American Journal of Psychiatry 1992; 149: 1183–1188
   PubMed Web of Science ®Google Scholar
• Crow T J, Macmillian J F, Johnson A L, Johnstone E C. A randomised trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986; 148: 120–127
   PubMed Web of Science ®Google Scholar
• Rabiner C J, Wegner J, Kane J M. Outcome of first-episode psychosis: 1. Relapse rates after 1 year. American Journal of Psychiatry 1986; 143: 1155–1158
   PubMed Web of Science ®Google Scholar
• Moscarelli M, Capri S, Neri L. Cost evaluation of chronic schizophrenic patients during the first 3 years after the first contact. Schizophrenia Bulletin 1991; 17: 421–426
   PubMed Web of Science ®Google Scholar
• Craig T J, Bromet E J, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. American Journal of Psychiatry 2000; 157: 60–66
   PubMed Web of Science ®Google Scholar
• Barnes T R, Hutton S B, Chapman M J, Mutsatsa S, Puri B K, Joyce E M. West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. British Journal of Psychiatry 2000; 177: 207–211
   PubMed Web of Science ®Google Scholar
• de Haan L, van Der Gaag M, Wolthaus J. Duration of untreated psychosis and the long-term course of schizophrenia. European Journal of Psychiatry 2000; 15: 264–267
   Web of Science ®Google Scholar
• Drake R J, Haley C J, Akhtar S, Lewis S W. Causes and consequences of duration of untreated psychosis in schizophrenia. British Journal of Psychiatry 2000; 177: 511–515
   PubMed Web of Science ®Google Scholar
• Larsen T K, Moe L C, Vibe-Hansen L, Johannessen J O. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophrenia Research 2000; 45: 1–9
   PubMed Web of Science ®Google Scholar
• Wyatt R J, Green M F, Tuma A H. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine 1997; 27: 261–268
   PubMed Web of Science ®Google Scholar
• May P R, Tuma A H, Yale C, Potepan P, Dixon W J. Schizophrenia –a follow-up study of results of treatment. Archives of General Psychiatry 1976; 33: 481–486
   PubMed Web of Science ®Google Scholar
• Lieberman J A, Koreen A R, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal of Clinical Psychiatry 1996; 57: 5–9
   PubMed Web of Science ®Google Scholar
• Docherty J P, Van Kammen D P, Siris S G, Marder S R. Stages of onset of schizophrenic psychosis. American Journal of Psychiatry 1978; 135: 420–426
   PubMed Web of Science ®Google Scholar
• Huber G, Gross G. The concept of basic symptoms in schizophrenia and schizoaffective psychoses. Recenti Progressi in Medicina 1989; 80: 646–652
   PubMedGoogle Scholar
• Foulds G, Bedford A. A hierachy of classes of personal illness. Psychological Medicine 1975; 5: 181–192
   PubMed Web of Science ®Google Scholar
• Herz M I, Glazer W M, Mostert M A, et al. Intermittent vs. maintenance medication in schizophrenia. Archives of General Psychiatry 1991; 48: 333–339
   PubMed Web of Science ®Google Scholar
• Subotnik K L, Neuchterlein K H. Prodromal signs and symptoms of schizophrenia relapse. Journal of Abnormal Psychology 1988; 97: 405–412
   PubMed Web of Science ®Google Scholar
• Norman R MG, Malla A K. Prodromal symptoms of relapse in schizophrenia: a review. Schizophrenia Bulletin 1995; 21: 527–539
   PubMed Web of Science ®Google Scholar
• Herz M I, Mellville C. Relapse in schizophrenia. American Journal of Psychiatry 1980; 137: 801–805
   PubMed Web of Science ®Google Scholar
• Kumar S, Thara R, Rajkumar S. Coping with symptoms of relapse in schizophrenia. European Archives of Psychiatry and Neurological Sciences 1989; 239: 213–215
   PubMedGoogle Scholar
• Thurm I, Haefner H. Percieved vulnerabiliy, relapse risk and coping in schizophrenia: An explorative study. European Archives of Psychiatry and Neurological Sciences 1987; 237: 46–53
   PubMedGoogle Scholar
• Hamera E K, Peterson K A, Young L M, Schaumloffel M M. Symptom monitoring in schizophrenia. Archives of General Psychiatry 1992; 6: 324–330
   Google Scholar
• Gaebel W, Frick U, Kopcke W, et al. Early neuroleptic intervention in schizophrenia. are prodromal symptoms valid predictors of relapse?. British Journal of Psychiatry 1993; 163(Suppl. 21)8–12
   Web of Science ®Google Scholar
• Jolley A G, Hirsch S R, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. British Medical Journal 1990; 301: 837–842
   PubMed Web of Science ®Google Scholar
• Carpenter W T, Hanlon T E, Heinrichs D W, et al. Continuous versus targeted medication in schizophrenic outpatients. American Journal of Psychiatry 1990; 147: 1138–1148
   PubMed Web of Science ®Google Scholar
• Bustillo J, Buchanan R W, Carpenter W T. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophrenia Bulletin 1995; 21: 553–559
   PubMed Web of Science ®Google Scholar
• Jolley A G, Hirsch S R, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients. British Medical Journal 1989; 298: 985–990
   PubMed Web of Science ®Google Scholar
• Birchwood M, Smith J, Macmillan F, et al. Predicting relapse in schizophrenia. the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychological Medicine 1989; 19: 649–656
   PubMed Web of Science ®Google Scholar
• Malla A K, Normam R MG. Prodromal symptoms in schizophrenia: a prospective investigation. British Journal of Psychiatry 1994; 164: 487–493
   PubMed Web of Science ®Google Scholar
• Jorgensen P. Schizophrenic delusions. the detection of warning signals. Schizophrenia Research 1998; 32: 17–22
   PubMed Web of Science ®Google Scholar
• Tarrier N, Barrowclough C, Bamrah J S. Prodromal signs of relapse in schizophrenia. Social Psychiatry and Psychiatric Epidemiology 1991; 26: 157–161
   PubMed Web of Science ®Google Scholar
• Marder S R, Mintz J, Van Putten T, Lebell M, Wirshing W C, Johnston-Cronk K. Early prediction of relapse in schizophrenia: An application of receiver operating characteristics (ROC) methods. Psychopharmacology Bulletin 1991; 27: 79–82
   PubMedGoogle Scholar
• Marder S R, Wirshing W C, Van Putten T, et al. Fluphenazine versus placebo for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry 1994; 51: 280–287
   PubMed Web of Science ®Google Scholar
• Herz M I, Glazer W M, Mirza M, Mostert M A, Havez H. Treating prodromal episodes to prevent relapse in schizophrenia. British Journal of Psychiatry 1989; 155(Suppl. 5)123–127
   PubMed Web of Science ®Google Scholar
• Carpenter W T, Buchanan R W, Kirkpatrick B, Brier A F. Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry 1999; 156: 299–303
   PubMed Web of Science ®Google Scholar
• Herz M I, Lamberti J S, Mintz J, et al. Program for relapse prevention in schizophrenia: a controlled study. Archives of General Psychiatry 2000; 53: 277–283
   Web of Science ®Google Scholar